Understanding Tysabri and Progressive Multifocal Leukoencephalopathy
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Specific Risk Awareness
If you or a loved one is taking Tysabri, understanding the signs of progressive multifocal leukoencephalopathy (PML) is critical for early detection. This page covers the symptoms, monitoring protocols, and risk factors associated with long-term Tysabri use, building on a broader tradition of informed patient education about pharmaceutical risks.
Understanding Tysabri and Its Association with PML
Tysabri (natalizumab) is a biologic medication approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently placed at the beginning of the prescribing information to alert healthcare professionals and patients to the serious nature of this adverse event. PML is caused by the reactivation of the JC virus in the brain, which typically occurs only in individuals who are immunocompromised. The FDA label notes that "progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability, has occurred in patients who have received TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanism linking Tysabri to PML involves the drug's effect on the immune system. Tysabri works by blocking the movement of immune cells into the brain, which reduces inflammation but also impairs the brain's ability to fight off infections like the JC virus. This immunosuppressive effect creates an environment where the virus can replicate unchecked, leading to the destruction of brain cells and the clinical symptoms of PML.
Risk Factors and Clinical Presentation of PML
Several risk factors have been identified that increase the likelihood of developing PML while on Tysabri. The FDA label specifies that "three factors that are known to increase the risk of PML in TYSABRI-treated patients have been identified: The presence of anti-JCV antibodies. Patients who are anti-JCV antibody positive have a higher risk for developing PML. Longer treatment duration, especially beyond 2 years" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, prior use of immunosuppressants is another risk factor. These factors should be considered when deciding whether to start or continue Tysabri therapy, weighing the potential benefits against the risk of PML. The clinical presentation of PML can vary, but common symptoms include progressive neurological deficits such as weakness, difficulty with coordination, vision changes, speech problems, and cognitive decline. The FDA label advises that "healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early diagnosis is critical, as prompt discontinuation of Tysabri and initiation of appropriate treatment may improve outcomes, though PML often leads to severe disability or death.
Timeline of PML Development and Adverse Event Reports
The timeline between exposure to Tysabri and the development of PML can vary. In clinical trials, PML occurred in patients who had received Tysabri for varying durations. The FDA label reports that "two cases of PML were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks. These two patients had received TYSABRI in addition to interferon beta-1a. The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that PML can occur after relatively short exposure, as well as after longer treatment periods, highlighting the need for continuous vigilance. Adverse event reports from the FDA Adverse Event Reporting System (FAERS) provide additional context on the range of side effects associated with Tysabri. The most frequently reported events include fatigue, multiple sclerosis relapse, headache, gait disturbance, and fall (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly indicate PML, they underscore the importance of monitoring for neurological symptoms that could be early signs of PML or other complications.
Legal Considerations for Tysabri-Related PML
For patients who have developed PML after taking Tysabri, legal considerations may arise regarding the adequacy of warnings provided by the manufacturer. The FDA boxed warning is a strong regulatory measure, but patients and their families may question whether they were fully informed of the risks before starting treatment. Attorney-related considerations for affected patients include evaluating whether the prescribing physician followed the TOUCH Prescribing Program, a restricted distribution program that requires documentation of patient education and monitoring. The FDA label states that "because of the risk of PML, TYSABRI is available only through a restricted distribution program called the TOUCH Prescribing Program" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not adequately informed about the risk of PML or if monitoring was insufficient, legal action may be pursued. In summary, Tysabri is associated with a significant risk of PML, a severe and often fatal brain infection. The FDA has mandated a boxed warning and a restricted distribution program to mitigate this risk. Patients and healthcare providers must remain vigilant for early signs of PML, especially in those with risk factors such as anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. For those affected, understanding the medical and legal aspects of this adverse event is crucial.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Tysabri and why is it associated with PML?
Tysabri (natalizumab) is a biologic medication used to treat multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the risk factors for developing PML while on Tysabri?
The FDA identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What legal options are available for patients who developed PML from Tysabri?
Patients may pursue legal action if they were not adequately warned about PML risks or if monitoring under the TOUCH Prescribing Program was insufficient. An attorney can evaluate whether the manufacturer or healthcare provider failed in their duty to inform (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.